Patient Capital

#### I. Institutional Overview Patient Capital Management, as evidenced by its Q4 2025 13F filing, presents a sophisticated psychological portrait of a high-conviction, value-oriented institutional investor. With a reported portfolio value of approximately **$2.59 billion** and a concentrated holding of only **40 stocks**, the institution operates with a philosophy that eschews the "closet indexing" prevalent in many large-scale asset management firms. Instead, Patient Capital adheres to a disciplined strategy of placing significant bets on a limited number of high-probability outcomes, a hallmark of "smart money" that prioritizes deep fundamental research over broad market exposure. The scale of the institution, sitting at $2.59 billion, places it in a "sweet spot" of institutional management. It is large enough to command significant resources and access to management teams, yet small enough to remain nimble, allowing it to build meaningful positions in mid-cap companies without causing excessive market impact. The portfolio’s concentration—averaging roughly **$64.7 million per holding**—suggests that each position is the result of rigorous vetting. When an institution holds only 40 stocks, the "hurdle rate" for a new idea to enter the portfolio is exceptionally high. This concentration indicates a belief that risk is mitigated not through the sheer number of holdings, but through the depth of understanding of each business’s competitive moat, cash flow durability, and valuation margin of safety. Analyzing the scale trend, the portfolio appears to be in a phase of strategic optimization. While the total number of stocks remains lean at 40, the internal movement within the portfolio—characterized by significant additions to existing winners and the aggressive pruning of laggards—suggests an active management style that is currently focused on "concentrating into conviction." The institution is not merely sitting on its hands; it is rotating capital from areas of perceived structural weakness or completed valuation reratings into areas of emerging opportunity. The psychological profile of Patient Capital is one of **calculated patience and contrarian resilience**. The name itself is a declaration of intent. In an era of high-frequency trading and quarterly performance obsession, this institution signals a willingness to endure short-term volatility in exchange for long-term compounding. However, the Q4 2025 data reveals that this patience is not synonymous with passivity. The massive reduction in certain high-profile names and the entry into new fintech and healthcare targets show a dynamic response to changing market conditions. The institution is currently positioned with a "barbell" approach: holding onto massive, cash-generative "ballast" stocks like **GOOGL (Alphabet)** and **AMZN (Amazon)** on one end, while making aggressive, contrarian bets on distressed or misunderstood assets like **BIIB (Biogen)** and **IAC (IAC Inc.)** on the other. In summary, Patient Capital enters 2026 as a highly focused investment vehicle that leverages its $2.59 billion AUM to execute a high-conviction strategy. It is an institution that views market volatility as an opportunity to upgrade the quality of its holdings, moving away from speculative growth or geographically complex assets toward high-quality domestic value and specialized healthcare plays. Its current state can be described as **"Aggressively Selective,"** maintaining a lean portfolio where every position must justify its place through a combination of fundamental strength and valuation upside. #### II. Sector Allocation Analysis The sector allocation of Patient Capital in Q4 2025 provides a clear window into its macro-economic outlook and its specific industry "bets." Unlike a diversified index fund, Patient Capital’s sector weights are highly idiosyncratic, reflecting a strong preference for sectors with tangible assets, intellectual property, or significant consumer ecosystems. | Sector | Weight (%) | Trend/Sentiment | | :--- | :--- | :--- | | Healthcare | 24.73 | Strong Overweight / Conviction | | Consumer Discretionary | 21.06 | Overweight / Cyclical Bet | | Communication Services | 15.66 | Core Allocation / Growth | | Financials | 15.57 | Core Allocation / Value | | Technology | 10.50 | Underweight / Selective Growth | | Energy | 7.72 | Tactical Exposure | | Industrials | 4.76 | Niche Exposure | **2.1 Concentration and Macro Judgment** The most striking feature of this allocation is the concentration in the top three sectors: **Healthcare, Consumer Discretionary, and Communication Services**. Together, these three sectors account for **61.45%** of the total portfolio. This level of concentration indicates a "thematic" approach to investing. The institution is not trying to "be the market"; it is trying to "beat the market" by identifying specific tailwinds in these areas. The **24.73% allocation to Healthcare** is particularly telling. In a period of economic uncertainty, healthcare often serves as a defensive anchor due to its non-discretionary nature. However, looking at the specific holdings (like Royalty Pharma and Biogen), it is clear that Patient Capital is not just buying "defensive" big pharma; it is buying **innovation and cash-flow intellectual property**. This suggests a macro judgment that while the broader economy may face headwinds, the structural demand for advanced therapeutics and the consolidation of healthcare royalties will continue to provide alpha. **2.2 The Consumer and Communication Pivot** The **21.06% weight in Consumer Discretionary** represents a bold bet on the resilience of the American consumer. By holding significant positions in companies like Amazon, Expedia, and Mattel, the institution is signaling that it does not subscribe to a "hard landing" recessionary thesis. Instead, it appears to be betting on a "K-shaped" recovery where dominant consumer platforms continue to gain market share despite inflationary pressures. The **15.66% in Communication Services** is dominated by Alphabet and Meta. This is the "digital infrastructure" play. Patient Capital views these companies not as volatile tech stocks, but as essential utilities of the modern age. The high weight here suggests a belief that the advertising market—the lifeblood of these firms—remains robust and that the AI-driven transformation of search and social media will lead to a new leg of growth. **2.3 Financials: The Value Anchor** With **15.57% in Financials**, the institution maintains a solid footing in the traditional value sector. The presence of Citigroup and JPMorgan, alongside newer fintech entries like Fiserv and Chime, indicates a diversified approach to the financial sector. This allocation suggests a judgment that the interest rate environment has stabilized at a level that is beneficial for net interest margins (NIM) for traditional banks, while the "digitization of money" continues to provide growth opportunities in the payments and fintech space. **2.4 Technology: A Notable Underweight** Perhaps the most contrarian aspect of the portfolio is the **10.50% weight in Technology**. In a market dominated by the "Magnificent Seven" and AI euphoria, an 10.5% tech weight is significantly lower than the S&P 500's tech weighting (which often exceeds 30%). This suggests that Patient Capital is wary of the "valuation froth" in the broader tech sector. They are not avoiding tech entirely—as evidenced by their NVIDIA and Alphabet holdings—but they are being extremely selective, preferring to own "tech-enabled" businesses in other sectors (like Amazon in Consumer Discretionary) rather than pure-play software or hardware firms at astronomical multiples. **2.5 Sector Rotation and Industry Trends** The data suggests a subtle but firm rotation. The institution is moving away from "global e-commerce" (evidenced by the massive reduction in Alibaba) and toward **"domestic fintech and specialized healthcare."** The shift into Biogen and the new positions in Fiserv and Chime indicate a move toward companies with specific, idiosyncratic catalysts rather than those dependent on broad global trade cycles. Furthermore, the **7.72% in Energy** (Energy Transfer, Seadrill, Noble Corp) shows a tactical commitment to the "old economy." This provides a hedge against inflation and geopolitical instability. By balancing high-growth communication services with cash-heavy energy and healthcare royalties, Patient Capital has constructed a portfolio that is designed to perform across various economic scenarios, provided their specific company-level theses hold true. #### III. To ---